[Treatment of an infection due to the intraperitoneal inoculation of mice with Pseudomonas aeruginosa with tobramycin and hyperimmune Pseudomonas aeruginosa plasma used per se and in combination].
Schemes for treating infections caused by intraperitoneal administration of P. aeruginosa to mice were tested. The animals were treated with tobramycin and hyperimmune pyocyanic plasma (HPP) used per se or in combination. In a dose of 5 mg/kg body weight tobramycin protected 72.9 per cent of the animals from death. HPP with a titer of the antipyocyanic antibodies of 1:320-1:160 had a stable 100 per cent protective effect on the infected animals. However, no complete elimination of P. aeruginosa from the host was observed. The combined use of tobramycin and HPP LD50 protected 97.23 per cent of the mice from lethal infection, the drugs being titrated for their separate use. The combined administration of tobramycin and HPP in treatment of mice with acute infection due to P. aeruginosa was more efficient than their use alone.
D000818:Animals; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D007116:Immunization, Passive / Q000379:methods*; D007274:Injections, Intraperitoneal; D051379:Mice; D011552:Pseudomonas Infections / Q000401:mortality / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000276:immunology*; D014031:Tobramycin / Q000627:therapeutic use*
D014031:Tobramycin
Lechenie infektsii, obuslovlennoĭ vnutribriushinnym zarazheniem mysheĭ Pseudomonas aeruginosa, tobramitsinom i giperimmunnoĭ sinegnoĭnoĭ plazmoĭ, primenennykh per se i v sochetanii.